Detalhe da pesquisa
1.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Ann Oncol
; 33(12): 1250-1268, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36228963
2.
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Ann Oncol
; 32(12): 1582-1589, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34500047
3.
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Ann Oncol
; 30(4): 558-566, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30689707
4.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Ann Oncol
; 34(1): 33-47, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307055
5.
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Ann Oncol
; 29(1): 154-161, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045554
6.
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Breast Cancer Res Treat
; 171(1): 21-31, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29736741
7.
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
Ann Oncol
; 27(6): 1013-1019, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26961146
8.
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.
Br J Cancer
; 106(12): 2016-24, 2012 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22669161
9.
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.
J Med Genet
; 48(1): 64-8, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20921021
10.
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Br J Cancer
; 104(8): 1356-61, 2011 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21427728
11.
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Breast Cancer Res Treat
; 119(2): 409-14, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19885732
12.
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Br J Cancer
; 101(8): 1456-60, 2009 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19707196
13.
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Br J Cancer
; 101(12): 2048-54, 2009 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19920816
14.
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
Breast Cancer Res Treat
; 118(3): 539-46, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19609668
15.
Clinical management of BRCA1 and BRCA2 mutation carriers.
Oncogene
; 25(43): 5825-31, 2006 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-16998496
16.
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
Fam Cancer
; 11(1): 69-75, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21898151
17.
Sex ratio skewing of offspring in families with hereditary susceptibility to breast cancer.
J Med Genet
; 42(6): 511-3, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15937087
18.
Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer.
J Appl Physiol (1985)
; 111(6): 1687-93, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21903887
19.
Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers.
J Med Genet
; 41(11): e120, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15520402
20.
Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Fam Cancer
; 8(1): 23-8, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-18758995